Given that TACE inevitably leads to tumor hypoxia-induced damage and enhanced expression of circulating or tissue vascular endothelial growth factor (VEGF), the addition of anti-angiogenic agents may exert complementary inhibitory effects on neovascularization and tumor growth.45 Liu et al46 combined sorafenib with TACE–HAIC, resulting in 6-month, 12-month, and 24-month PFS rates of 75.0%, 54.7%, and 30.0%, respectively, demonstrating significant efficacy and good tolerability in unresectable HCC patients. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.